Browse the search results

Page 2 of 51
    1. Human Biology and Medicine

    Overcoming mutation-based resistance to antiandrogens with rational drug design

    Minna D Balbas et al.
    Mutagenesis studies identified an androgen receptor mutation that converts enzalutamide-a drug recently approved for the treatment of advanced prostate cancer-into an androgen receptor agonist, and modeling studies informed the design of novel drugs that are effective against the mutant receptor.
    1. Cell Biology
    2. Human Biology and Medicine

    Polo-like kinase 1 induces epithelial-to-mesenchymal transition and promotes epithelial cell motility by activating CRAF/ERK signaling

    Jianguo Wu et al.
    Overexpression of PLK1 triggers oncogenic transformation and transcriptional reprogramming of prostate epithelial cells, which stimulates cell migration and invasion.
    1. Cancer Biology

    Selective eradication of cancer displaying hyperactive Akt by exploiting the metabolic consequences of Akt activation

    Veronique Nogueira et al.
    Exploiting the metabolic consequences of Akt activation in prostate cancer for therapeutic interventions that circumvent Akt inhibition therapy.
    1. Cancer Biology

    Replication Study: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44

    Xuefei Yan et al.
    Editors' Summary: This Replication Study did not reproduce those experiments in the original paper that it attempted to reproduce.
    1. Chromosomes and Gene Expression

    Androgen-regulated transcription of ESRP2 drives alternative splicing patterns in prostate cancer

    Jennifer Munkley et al.
    The male steroid hormone testosterone regulates splicing patterns by controlling the expression of a key splicing regulator protein.
    1. Cell Biology
    2. Human Biology and Medicine

    Prostate Cancer: SPOP the mutation

    Leah Rider, Scott D Cramer
    Insight
    Available as:
    • HTML
    • PDF
    1. Human Biology and Medicine

    Cancer: Designer antiandrogens join the race against drug resistance

    Jatinder S Josan, John A Katzenellenbogen
    Insight
    Available as:
    • HTML
    • PDF
    1. Cancer Biology
    2. Human Biology and Medicine

    Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death

    Haley Hieronymus et al.
    The percentage of a tumor’s genome with alterations in copy number is correlated with increased mortality across a range of tumor types and can be measured using a clinically approved sequencing assay.